New hib vaccine shows promise in infant trial
NCT ID NCT02140047
First seen Jan 07, 2026 · Last updated May 10, 2026 · Updated 25 times
Summary
This study tested a new vaccine called MT-2301 to protect healthy infants against Haemophilus influenzae type b (Hib) disease. The vaccine was given alongside routine DPT-IPV shots, and its safety and ability to produce protective antibodies were compared to an existing Hib vaccine (ActHIB). A total of 154 infants participated. The goal was to see if the new vaccine works as well as the current one.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMOPHILUS INFLUENZA TYPE B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational site
Fukuoka, Fukuoka, Japan
Conditions
Explore the condition pages connected to this study.